The effect of type II diabetes mellitus on platelet aggregation in patients who underwent percutaneous transluminal coronary angioplasty

Coronary Artery Disease

Volumn 13, Issue 1, 2002, Pages 45-48

  Saǧcan, Abdi ^a   Nalbantgil, Sanem ^a   Omay, Serdar Bedii ^a   Akin, Mustafa ^a  

^a NONE   (Turkey)

Author keywords

Collagen; Percutaneous transluminal coronary angioplasty; Platelet aggregation; Type II diabetes mellitus

Indexed keywords

ANTITHROMBOCYTIC AGENT; COLLAGEN; GUANYLATE CYCLASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; IN VITRO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONPARAMETRIC TEST; PRIORITY JOURNAL; RESTENOSIS; STUDENT T TEST; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TURBIDIMETRY;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COLLAGEN; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 0036209159     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200202000-00006     Document Type: Article

References (23)

1. Platelet membrane activation markers are predictive for increased risk of acute schemic event after PTCA
2. Platelet accumulation in experimental angioplasty: Time course and relation to vascular injury
3. Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilation
4. Blood platelet function, plasma serotonin and lipid metabolism in patients with diabetic nephropathy
5. Increased platelet aggregation in early diabetes mellitus
6. Platelet aggregation and retinal microangiopathy in diabetes and hypertension
7. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients
8. Role of platelet-inhibitor agents in coronary artery disease
9. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty
10. Platelet function
11. Platelet activation in unstable coronary disease
12. Do platelets have anything to do with diabetic microvascular disease?
13. The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM
14. Effect of insulin treatment in streptozocin-induced diabetic rats on in vitro platelet function and plasma von Willebrand factor activity and factor VIII-related antigen
15. Insulin increases guanosine 3′, 5′-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect
16. Blood coagulation/fibrinolytic disorders in diabetic patients
17. Hemobiological activity of gliclazide in diabetes mellitus
18. Gliclazide: Review of metabolic and vascular action
19. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy
20. Abciximab, ticlopidine, and concomittant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles undergoing percutaneous coronary intervention
21. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation
22. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
23. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial